Faculty

Institution

Unit

Venue

Timothy C. Thompson

The University of Texas MD Anderson Cancer Center

Affiliations

Division Of Medical Oncology

The University of Texas MD Anderson Cancer Center

NoneTimothy C. Thompson is currently serving as a Division Of Medical Oncology faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Timothy C. Thompson

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

prostate cancer urology oncology cancer research tumor biology cell biology oncogenes cancer cells molecular cancer radiation oncology medicinal research prostatic disease cancer biology cancer discovery pharmacology cancer treatment carcinogenesis gene therapy therapeutic targets genitourinary cancers cancer letter cancer care jama oncology metastasis cancer genetics radiation therapy cellular therapy vascular biology molecular diagnostics mammalian biology tumor targeting tumor suppressors pharmacotherapy signaling pathways benign prostatic hyperplasia cancer genomics viral oncology anti-cancer agents radiation biology enzyme inhibition surgical oncology cancer management hormonal therapy molecular cell biology apoptosis cell regulation drug targeting prostate cancer progression situ gene therapy cancer growth endocrine oncology clinical radiation oncology active surveillance perineural invasion therapeutic efficacy novel therapies protein expression castration-resistant prostate cancer localized prostate cancer prostate cancer patients radical prostatectomy human pathology endocrine-related cancers hormonal receptor t-regulatory cell disease progression human prostate cancer prostatic hyperplasia androgen receptor urological research andrology therapeutic effect intensity-modulated radiotherapy tumor aggressiveness peripheral blood leukocytes mouse model medicine systems biology ovarian cancer pathology

Notable Scholarly Works

Notable Federal Grants

Collaborators

C3NIRA: Randomized Phase II Study of Carboplatin-Cabazitaxel-Cetrelimab (Anti-Pd-1) Induction Followed by Niraparib +/- Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers (Avpc).. Journal of Clinical Oncology (2025)

pharmacologycancer immunotherapyurologymolecular cancercancer treatmentoncogenesgenitourinary cancersoncologytherapeutic targetspharmacotherapyprostatic diseasecancer carephase ii studyprostate cancer

Supplementary Table S9 From Spop Mutations Target Sting1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to Parp Inhibitor–Induced Growth Suppression. (2025)

cancer biologymolecular cell biologymolecular cancercancer cellscreate therapeutic vulnerabilitiesoncogenesprostate cancersupplementary table s9molecular biologycancer geneticscell signalingtumor biologysignaling pathwayscell biologytherapeutic targets

Targeting Highly Aggressive Ductal Prostate Tumours With Poly Adp Ribose Polymerase Inhibitor (Parpi) and Androgen Receptor Signaling Inhibitor (Arsi) Combination Therapy.. Journal of Clinical Oncology (2025)

pharmacologyurologymolecular cancerandrogen receptoroncogenesgenitourinary cancersoncologytherapeutic targetsprostatic diseasecancer cellscombination therapyprostate cancer

Vesicle-Mediated Mitochondrial Clearance Presents an Actionable Metabolic Vulnerability in Triple-Negative Breast Cancer. Cell Reports Medicine (2025)

molecular cancertriple-negative breast cancerbreast cancercancer cellsbreast oncologycell metabolismmolecular metabolismmolecular biologytumor biologyactionable metabolic vulnerabilitycell biologymetabolic remodelingmetabolic pathways

Validation of a Prognostic Blood-Based Sphingolipid Panel for Men With Localized Prostate Cancer Followed on Active Surveillance. Biomarker Research (2024)

Justin R. GreggLisa NewcombRanran WuJennifer DennisonJohn W. DavisCurtis PettawayLouis PistersJohn F. WardBrian F. ChapinLisly ChéryAhmet UrkmezAndrew M. FangNoel HiggasonPatricia TroncosoCarrie R. DanielChristopher LogothetisTimothy C. ThompsonAndrew W. HahnMenghan LiuYingye ZhengDan W. LinSamir HanashEhsan IrajizadJohannes Fahrmann

urologycancer researchbiomarkersbiomarker (medicine)active surveillanceprognostic biomarkersprostate cancerlocalized prostate cancer

Avpc Molecular Signature Supplementary Figures From Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. (2023)

pathologyurologymolecular canceroncogenesgenitourinary cancersmolecular medicineoncologycancer geneticstumor biologyprostatic diseasecancer cellsmolecular diagnosticsprostate cancer

Data From Caveolin-1–Lrp6 Signaling Module Stimulates Aerobic Glycolysis in Prostate Cancer. (2023)

urologycancer biologycancer cellssignal transductioncell metabolismbiochemistrymetabolic pathwaystumor biologycell signalingsignaling pathwaysprostatic diseasecell biologymetabolic remodelingcellular biochemistryprostate cancer

Data From Caveolin-1 Promotes Autoregulatory, Akt-Mediated Induction of Cancer-Promoting Growth Factors in Prostate Cancer Cells. (2023)

urologycancer biologymolecular cancercaveolin-1 promotes autoregulatorycancer cellsoncogenescell signalingtumor biologysignaling pathwayscell biologyprostate cancer cellscancer-promoting growth factorsprostate cancercancer growth

Data From Caveolin-1 Upregulation Contributes to C-Myc–Induced High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. (2023)

Guang YangAlexei A. GoltsovChengzhen RenShinji KurosakaKohei EdamuraRichard LogothetisFrancesco J. DeMayoPatricia TroncosoJorge BlandoJohn DiGiovanniTimothy C. Thompson

urologyprostatic diseaseprostate cancer

Data From Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. (2023)

urologymolecular canceroncogenesgenitourinary cancersoncologyradiation oncologycancer geneticsprostatic diseasemolecular diagnosticsprostate cancer

1
2
3
4
5
29
10 / page

Timothy C. Thompson

The University of Texas MD Anderson Cancer Center

Affiliations

Division Of Medical Oncology

The University of Texas MD Anderson Cancer Center

NoneTimothy C. Thompson is currently serving as a Division Of Medical Oncology faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Timothy C. Thompson

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Supplementary Table S9 From Spop Mutations Target Sting1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to Parp Inhibitor–Induced Growth Suppression. (2025)

pharmacologyurologymolecular cancerandrogen receptoroncogenesgenitourinary cancersoncologytherapeutic targetsprostatic diseasecancer cellscombination therapyprostate cancer

Vesicle-Mediated Mitochondrial Clearance Presents an Actionable Metabolic Vulnerability in Triple-Negative Breast Cancer. Cell Reports Medicine (2025)

Validation of a Prognostic Blood-Based Sphingolipid Panel for Men With Localized Prostate Cancer Followed on Active Surveillance. Biomarker Research (2024)

urologycancer researchbiomarkersbiomarker (medicine)active surveillanceprognostic biomarkersprostate cancerlocalized prostate cancer

Avpc Molecular Signature Supplementary Figures From Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. (2023)

pathologyurologymolecular canceroncogenesgenitourinary cancersmolecular medicineoncologycancer geneticstumor biologyprostatic diseasecancer cellsmolecular diagnosticsprostate cancer

Data From Caveolin-1–Lrp6 Signaling Module Stimulates Aerobic Glycolysis in Prostate Cancer. (2023)

Data From Caveolin-1 Promotes Autoregulatory, Akt-Mediated Induction of Cancer-Promoting Growth Factors in Prostate Cancer Cells. (2023)

Data From Caveolin-1 Upregulation Contributes to C-Myc–Induced High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. (2023)

Guang YangAlexei A. GoltsovChengzhen RenShinji KurosakaKohei EdamuraRichard LogothetisFrancesco J. DeMayoPatricia TroncosoJorge BlandoJohn DiGiovanniTimothy C. Thompson

urologyprostatic diseaseprostate cancer

Data From Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. (2023)

urologymolecular canceroncogenesgenitourinary cancersoncologyradiation oncologycancer geneticsprostatic diseasemolecular diagnosticsprostate cancer

1
2
3
4
5
29
10 / page